LIDEX Drug Patent Profile

When do Lidex patents expire, and when can generic versions of Lidex launch?

Lidex is a drug marketed by Alvogen and is included in three NDAs.

The generic ingredient in LIDEX is fluocinonide. There are nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the fluocinonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lidex

A generic version of LIDEX was approved as fluocinonide by SUN PHARMA CANADA on June 10^th, 1987.

Summary for LIDEX

US Patents:	0
Applicants:	1
NDAs:	3

US Patents and Regulatory Information for LIDEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alvogen	LIDEX	fluocinonide	CREAM;TOPICAL	016908-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Alvogen	LIDEX-E	fluocinonide	CREAM;TOPICAL	016908-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Alvogen	LIDEX	fluocinonide	OINTMENT;TOPICAL	016909-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Alvogen	LIDEX	fluocinonide	SOLUTION;TOPICAL	018849-001	Apr 6, 1984		DISCN	Yes	No

International Patents for LIDEX

See the table below for patents covering LIDEX around the world.

Country	Patent Number	Title	Estimated Expiration
Yugoslavia	268471
Netherlands	154665
Switzerland	566783
Norway	129078
Sweden	377042

LIDEX Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is LIDEX and Its Market Position?

LIDEX is the trade name for the corticosteroid fluocinonide, used primarily for inflammation, itching, and allergic reactions. It is available in topical formulations including creams, ointments, gels, and solutions. LIDEX competes within the corticosteroid market segment, with competition from brands like Lidex-E, Kenalog, and Temovate.

What Is the Nature of the Investment Proposition?

Investing in LIDEX involves analyzing both the pharmaceutical market dynamics for topical corticosteroids and the potential for patent protection and lifecycle management. Its revenue outlook depends on:

• Market penetration in dermatological indications
• Competitive landscape and generic entry timelines
• Regulatory exclusivity periods
• Pricing strategies and reimbursement policies

How Does LIDEX's Patent and Regulatory Status Impact Investment?

LIDEX's original patents have expired in several key markets, leading to generic competition. However, formulation patents or exclusivity agreements can extend revenue streams.

• Patent expiration timelines: In the US, patent protection generally expired, opening the market to generics.
• Regulatory exclusivity: Data exclusivity in the US lasts five years from approval, but this has likely elapsed post-approval, making generics legally permissible.
• Market exclusivity in Europe: Usually up to ten years, subject to variations.

Manufacturers with formulation or delivery device patents may maintain market exclusivity, creating opportunities for brand retention.

What Are the Key Drivers of Revenue and Profitability?

• Market share in select indications: Dermatology prescriptions vary regionally; high-volume markets influence sales.
• Pricing power: Brand recognition allows for premium pricing over generics.
• Generic competition: Entry reduces prices and margins substantially.
• Cost management: Manufacturing costs, marketing expenditure, and distribution play roles in profitability.

The shift toward generics impacts revenue, but branding and formulation improvements can sustain a premium segment.

What Are the Main Risks and Competitive Threats?

• Generic erosion: Loss of market share post-patent expiry.
• Regulatory changes: Reimbursement reforms and safety warnings for corticosteroids.
• Market saturation: Limited expansion opportunities for a mature product.
• Pipeline development: Absence of next-generation formulations limits growth.

Patents on formulation or delivery devices, or development of new indications, can mitigate these risks.

What Is the Investment Outlook, Considering Industry Trends?

• Market size: The global topical corticosteroid market was valued at approximately $2.5 billion in 2022, with a CAGR of around 4% (source: MarketsandMarkets).
• Growth prospects: Limited for branded LIDEX post-generic entry but potentially attractive in emerging markets with lower generic penetration.
• Competing innovations: Novel corticosteroids or non-steroidal alternatives threaten established products.

Pharmaceutical companies focusing on lifecycle management, such as reformulations or combination therapies, may create new revenue streams.

How Do Regulatory and Patent Strategies Influence Investment?

Patents and regulatory exclusivities are critical to maintaining market share. Strategies include:

• Filing for patents on formulation specifics, delivery mechanisms, or formulations with extended-release properties.
• Securing orphan drug status for specific indications to extend exclusivity.
• Early submission for regulatory approval of new formulations or indications.

The timing of patent expiries and regulatory decisions dramatically affects potential returns.

What Are the Financial and Strategic Metrics to Monitor?

• Sales growth and market share in key regions.
• Patent status updates and expiration timelines.
• Pricing trends and reimbursement policies.
• Pipeline progress for new formulations or indications.
• Competitive actions, including patent defenses or litigation outcomes.

Monitoring these metrics informs valuation and strategic positioning.

Closing Summary

LIDEX presents a mature product with a finite patent life and imminent generic competition in major markets. Investment opportunities hinge on managing patent protections, leveraging formulation innovations, and expanding into emerging markets. The product's revenue prospects are declining in developed markets but may find growth niches elsewhere. Manufacturers' strategies to extend lifecycle through formulation patents or pipeline developments remain key.

Key Takeaways

• LIDEX is a corticosteroid with a significant patent expiry exposure, subject to generic competition.
• Revenue dynamics depend on market share, pricing, and exclusivity protections.
• Patent strategies and regulatory exclusivities are critical to maintaining profitability.
• Industry trends favor lifecycle extension through formulation or indication patents.
• Growth opportunities are primarily in emerging markets and novel formulations.

FAQs

1. When did LIDEX's primary patents expire?
   Patent expiration varies by jurisdiction; in the US, most formulation patents expired around 2010-2015, allowing generic entry.

2. Are there ongoing pipeline projects for LIDEX?
   No publicly known pipeline projects specific to LIDEX exist; lifecycle extensions focus on formulation enhancements.

3. What is the competitive landscape for topical corticosteroids?
   It includes numerous generics, with branded products maintaining niche segments via formulation or delivery device patents.

4. How do reimbursement policies affect LIDEX sales?
   Reimbursement influences prescribing patterns; stricter controls in some markets may reduce prescribing volumes.

5. What is the potential for market growth outside established markets?
   Emerging markets with less generic penetration may offer growth opportunities, especially with local manufacturing and distribution.

---

Sources

[1] MarketsandMarkets. "Topical Corticosteroids Market by Type, Application, Region - Global Forecast to 2027."